Folate intake and incidence of hypertension among American young adults: a 20-y follow-up study by Xun, Pengcheng et al.
Folate intake and incidence of hypertension among American young
adults: a 20-y follow-up study1–3
Pengcheng Xun, Kiang Liu, Catherine M Loria, Deborah Bujnowski, James M Shikany, Pamela J Schreiner,
Stephen Sidney, and Ka He
ABSTRACT
Background: Laboratory studies suggest that folate intake may
decrease blood pressure (BP) through increasing nitric oxide syn-
thesis in endothelial cells and/or reducing plasma homocysteine
concentrations. However, human studies, particularly longitudinal
data, are limited.
Objective: Our objective was to investigate whether dietary folate
intake is associated with the 20-y incidence of hypertension.
Design: We prospectively followed 4400 men and women (African
Americans and whites aged 18–30 y) without hypertension at base-
line (1985) in the Coronary Artery Risk Development in Young
Adults study 6 times, in 1987, 1990, 1992, 1995, 2000, and 2005.
Diet was assessed by dietary-history questionnaire at baseline and in
1992 and 2005. Incident hypertension was defined as the first oc-
currence at any follow-up examination of systolic BP 140 mm Hg,
diastolic BP 90 mm Hg, or use of antihypertensive medication.
Results: A total of 989 incident cases were identified during the
20-y follow-up. After adjustment for potential confounders, partic-
ipants in the highest quintile of total folate intake had a significantly
lower incidence of hypertension (HR: 0.48; 95% CI: 0.38, 0.62; P-
trend , 0.01) than did those in the lowest quintile. The multivari-
able HRs for the same comparison were 0.33 (95% CI: 0.22, 0.51;
P-trend , 0.01) in whites and 0.54 (95% CI: 0.40, 0.75; P-trend ,
0.01) in African Americans (P-interaction = 0.047). The inverse
associations were confirmed in a subset of the cohort (n = 1445)
with serum folate measured at baseline and in 1992 and 2000.
Conclusions: Higher folate intake in young adulthood was longitu-
dinally associated with a lower incidence of hypertension later in life.
This inverse association was more pronounced in whites. Additional
studies are warranted to establish the causal inference. Am J Clin Nutr
2012;95:1023–30.
INTRODUCTION
Hypertension, a health disorder and a major risk factor for
other chronic diseases, has become an important public health
challenge worldwide (1–3). Therefore, identifying potential
protective or risk factors for hypertension is of great public health
significance.
Laboratory studies suggest that folate intake may have ben-
eficial effects on blood pressure (BP)4 by increasing nitric oxide
synthesis in endothelial cells and/or reducing plasma homo-
cysteine concentrations (4, 5). A meta-analysis of 12 small
(from 17 to 100 participants), randomized controlled trials
showed that high-dose (5000 lg/d) folic acid supplementation
for 2 to 16 wk can significantly lower systolic BP with a mean
reduction of 22.03 mm Hg (95% CI: 23.63, 20.43) (6). An-
other placebo-controlled study indicated that high-dose (15 mg/
d) folate administration for 3 wk significantly decreased both
systolic and diastolic BP in postmenopausal women (7). How-
ever, longitudinal data are limited. One 8-y follow-up study
using data from the Nurses’ Health Study I (subjects aged 27–44 y)
and II (subjects aged 43–70 y) is the only published large-scale
study in which an inverse association between folate intake and
incident hypertension (defined based on self-reported BP) was
documented (8). Therefore, we prospectively examined folate
intake in relation to incidence of hypertension in a large biracial
cohort of American men and women over 20 y follow-up using
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the evolution of cardiovascular disease (CVD) risk factors among
5115 young adults aged 18–30 y at baseline in 1985. Participants
were enrolled from 4 US metropolitan cities: Birmingham, AL;
Chicago, IL; Minneapolis, MN; and Oakland, CA. Sampling was
designed to achieve approximately equal distributions across age
(18–24 or 25–30 y), sex, race (African American or white), and
education (high school or less, greater than high school). The
details of the study design and recruitment protocol were de-
scribed elsewhere (9). To date, 6 follow-ups have been conducted,
in 1987, 1990, 1992, 1995, 2000, and 2005. Follow-up rates
averaged .90%, and ;70% of the participants in the original
cohort returned in 2005. The study was approved by the in-
stitutional review boards of the centers involved. All participants
provided written informed consent.
In the current study, exclusions included missing data on folate
intake (n = 4), implausible total energy intake (,800 or .8000
kcal/d for men and ,600 or .6000 kcal/d for women; n = 128),
and diagnosed hypertension (n = 140) at baseline. Participants
were also excluded if they lacked information for defining hy-
pertension (n = 177) or were pregnant at any examination (n =
226). After these exclusions, 4440 participants remained in the
analysis.
Ascertainment of folate intake
The CARDIA dietary-history questionnaire, an interviewer-
administered quantitative food-frequency questionnaire, was
designed to assess habitual eating patterns. The validity and
reproducibility of the CARDIA dietary history have been eval-
uated and discussed elsewhere (10, 11). Dietary assessment was
conducted 3 times at baseline and examination year 7 and year 20.
Participants were asked to recall their usual dietary intakes over
the past month. They were asked general questions about their
diet, which elicited specific foods consumed in an open-ended
fashion. They were then asked to report the frequency, amount of
food consumption, and method of preparation for each item
named. Information on folate-containing supplements was also
collected. Values for total folate and other B vitamin intake
included dietary and supplemental sources. Folate intake was
measured 3 times at baseline and follow-ups in 1992 (year 7) and
2005 (year 20), and intakes of vitamins B-6 and B-12 were
assessed in 1992 and 2005.
Ascertainment of serum folate, vitamin B-6, vitamin B-12,
and homocysteine concentrations
Serum samples were collected from baseline and in 1992 and
2000 in a subset of the cohort (n = 1445) and stored at 270C
until analysis. Serum folate and vitamin B-12 were measured on
the Hitachi 911 (Roche Diagnostics) by using the CEDIA ho-
mogeneous enzyme immunoassay system (Boehringer Man-
nheim). Intra- and interassay CVs were 4.3% and 6.7% for folate
and 4.1% and 6.2 for vitamin B-12. Serum vitamin B-6 was
measured by using a radioenzymatic assay (American Labora-
tory Products). Intra- and interassay CVs were 6.3% and 10.1%,
respectively. Serum homocysteine was measured by a fluores-
cence polarization immunoassay (IMx Homocysteine Assay;
Axis Biochemicals ASA) by using the IMx analyzer (Abbott
Diagnostics) (12). The intra- and interassay CVs were 1.9% and
4.1%, respectively. All ascertainments were conducted in the
Advanced Research and Diagnostic Laboratory, University of
Minnesota.
The characteristics of the subset were generally similar to
those of the entire cohort (data not shown). To assess how well
folate intake represents body stores of folate, we calculated the
Spearman correlation (rs = 0.49) between the average of folate
intake (dietary source plus supplemental source) and the mean
concentration of serum folate in this subcohort.
Ascertainment of other covariates
Demographic variables, including age, sex, race, and educa-
tion level, were collected by using a self-administered ques-
tionnaire and verified during clinic examinations. Smoking status
was determined on the basis of self-report, and participants were
classified as never, former, or current smokers. Current smokers
were further classified into 3 groups based on the pack-year (0–4,
5–10, or 11 pack-years). Alcohol consumption was measured
by using a validated questionnaire and was categorized into 4
groups: 0 (never drink), 0.1–14.9, 15.0–29.9, or 30 g/d physi-
cal activity (PA) was assessed by using the CARDIA Physical
Activity History Questionnaire, an interviewer-administered self-
report of frequency of participation in 13 categories of recrea-
tional sports, exercise, leisure, and occupational activities over
the previous 12 mo. PA score was calculated in exercise units on
the basis of the frequency and duration of activity over the pre-
vious year. A score of 100 exercise units is roughly equivalent to
engaging in vigorous activity for 2 to 3 h/wk, 6 mo of the year
(13–15).
Ascertainment of hypertension
BP was measured at baseline and at the first 5 follow-up
examinations by using the Hawksley random-zero sphygmo-
manometer (W. A. Baum Co) and at the seventh examination
(year 20) by using the OmROn HEM907XL by trained and
certified technicians (16). Three BP measurements were taken
from the right arm of each participant at 1-min intervals after
a 5-min seated rest. Systolic and diastolic BPs were recorded as
phase I and V Korotkoff sounds through year 15. On the basis of
a study of ;900 participants, we estimated systolic BP (random
zero = 3.74 + 0.96 · observed OmROn systolic BP and estimated
diastolic BP = 1.30 + 0.97 · observed OmROn diastolic BP at
year 20 (17, 18). The second and third of these measurements
were averaged for analysis.
Hypertension was defined by using the Seventh Report of the
Joint National Committee on Detection, Evaluation, and Treat-
ment of High Blood Pressure (JNC 7) cutoff as a systolic BP
140 mm Hg, a diastolic BP 90 mm Hg, or use of antihy-
pertensive medication at that examination. Incident hypertension
was defined at the first follow-up examination, at which a par-
ticipant met 1 of the above 3 criteria.
Statistical analysis
All analyses were performed by using SAS 9.2 (SAS Institute
Inc). Two-sided tests were used and P  0.05 was considered
statistically significant. Chi-square test, ANOVA, and Kruskal-
Wallis test were used to compare the baseline characteristics of
participants according to quintiles of folate intake within each
race subgroup as appropriate.



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































FOLATE INTAKE AND HYPERTENSION 1025
Cox regression analysis was used to examine folate intake in
relation to incident hypertension. Follow-up time was calculated
as the difference between the baseline and the year when hy-
pertension was first identified, examination year 20, or the year
a participant was censored, whichever came first (19). To reduce
measurement error caused by within-person variation and to best
represent long-term dietary intake, we used cumulative average
intake of nutrients or foods. For example, we related folate intake
reported at baseline to new hypertension cases identified at year 2
and year 5 and the average of folate intake reported at baseline
and year 7 and year 20 to new cases identified at year 20. We
categorized exposures of interest into quintiles based on their
distribution. We used a sequential covariate-adjusted strategy in
the analysis: model 1 adjusted for age, sex, race, and study center,
and model 2 additionally adjusted for BMI, education, smoking
status, alcohol consumption, PA, family history of hypertension,
and dietary intakes of total energy, sodium, potassium, calcium,
a-linolenic acid, linoleic acid, and long-chain omega-3 (n23)
fatty acids. We also verified the association between cumulative
average serum folate concentrations and incident hypertension
in a subset of the cohort by using a similar sequential strategy.
In addition, we investigated whether race and sex modified the
association, because some previous studies indicated that race
and sex may modify the folate-CVD (20) or the homocysteine-
hypertension relation (21). These analyses were performed by
creating interaction terms for folate intake with these potential
modifiers. The P values for interaction were calculated from
a likelihood ratio test by comparing models with and without the
interaction terms. Moreover, propensity scores were used to
balance the observed covariates between participants from the
study groups (eg, 2 extreme quintile groups) to mimic what
happens in a randomized study in a sensitivity analysis (22).
Furthermore, to explore potential mechanisms, we 1) examined
the relation between serum concentrations of folate and homo-
cysteine by using Spearman partial correlation analysis, 2) as-
sessed homocysteine concentrations in relation to BP by using
generalized estimating equations, and 3) determined the asso-
ciation of homocysteine concentrations with incident hyperten-
sion by using the Cox regression model.
RESULTS
During 70,738 person-years of follow-up, 989 incident cases of
hypertension were identified (incident rate = 0.014/person-year).
Of them, 577 were newly diagnosed by research staff at follow-up
visits, and 412 were those already diagnosed before a follow-up
visit. At baseline, the mean (6SD) age of the study population
was 24.96 3.6 y, and the mean (6SD) BMI (in kg/m2) was 24.56
5.0. Considering that racial differences in the hypertension rate
due to different lifestyles were previously determined in CARDIA
(23), we described baseline characteristics of the study pop-
ulation stratified by race (Table 1). Compared with participants
in the lowest quintile of folate intake, those in the highest quintile
were slightly older, were more likely to be females and non-
current smokers, and had a relatively higher education level and
lower alcohol consumption among both African Americans and
whites. In addition, those with a high folate intake were more
likely to be active and lean among whites but not among African
Americans.
As illustrated in Table 2, folate intake was inversely associ-
ated with incidence of hypertension. The inverse association
became statistically significant from the second quintile and
strengthened slightly from the third to fifth quintiles. Partici-
pants in the highest quintile of folate intake had a significantly
lower incidence of hypertension (HR: 0.48; 95% CI: 0.38, 0.62;
P-trend , 0.01) than did those in the lowest quintile after
TABLE 2
Multivariable-adjusted HRs (95% CIs) of incident hypertension by quintile of total folate intake1
Quintile of energy-adjusted total folate intake
P-trend21 (lowest) 2 3 4 5 (highest)
Folate intake (lg  1000 kcal21  d21)3 91.8 (79.8–102.3) 129.6 (120.4–139.3) 169.5 (159.1–181.1) 226.4 (210.0–247.5) 353.0 (302.3–454.3)
Overall cohort (n = 4440)
No. of events/participants 276/888 240/888 180/888 142/888 151/888
Model 14 1.00 0.61 (0.51, 0.72) 0.43 (0.36, 0.53) 0.34 (0.28, 0.42) 0.38 (0.31, 0.47) ,0.01
Model 25 1.00 0.63 (0.52, 0.76) 0.48 (0.38, 0.59) 0.41 (0.32, 0.52) 0.48 (0.38, 0.62) ,0.01
Whites (n = 2214)
No. of events/participants 65/244 59/344 59/466 65/560 73/600
Model 14 1.00 0.38 (0.27, 0.55) 0.26 (0.18, 0.37) 0.22 (0.15, 0.31) 0.24 (0.17, 0.35) ,0.01
Model 25 1.00 0.49 (0.33, 0.72) 0.30 (0.20, 0.45) 0.29 (0.19, 0.44) 0.33 (0.22, 0.51) ,0.01
African Americans (n = 2226)
No. of events/participants 211/644 181/544 121/422 77/328 78/288
Model 14 1.00 0.67 (0.55, 0.82) 0.51 (0.40, 0.63) 0.39 (0.30, 0.51) 0.46 (0.35, 0.60) ,0.01
Model 25 1.00 0.67 (0.54, 0.83) 0.54 (0.42, 0.69) 0.46 (0.34, 0.62) 0.54 (0.40, 0.75) ,0.01
1 All models were constructed by using Cox proportional hazards regression analysis.
2 Ordinal variables using medians in each quintile were created for the trend tests.
3 Values are medians; IQRs in parentheses.
4 Adjusted for age, sex, race (African American or white), and study center. Race was adjusted for only in the overall cohort.
5 Additionally adjusted for BMI (continuous), physical activity (quintile), education (,12, 12–15.9, or 16 y), smoking status (nonsmokers, former
smokers, or current smokers with pack-years between 1 and 4, between 5 and 10, or 11 y), alcohol consumption (0, 0.1–14.9, 15.0–29.9, or 30 mL/d),
family history of hypertension (yes or no), and dietary intakes (quintiles) of total energy, sodium, potassium, calcium, a-linolenic acid, linoleic acid, and long-
chain omega-3 fatty acids.
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adjustment for potential confounders. The multivariable HRs for
the same comparison were 0.33 (95% CI: 0.22, 0.51; P-trend ,
0.01) in whites and 0.54 (95% CI: 0.40, 0.75; P-trend , 0.01) in
African Americans (P-interaction = 0.047). Sex did not appre-
ciably modify the association (P-interaction = 0.44).
We considered the potential effect of supplement use. When
we further adjusted folic acid–containing supplement use status
(yes or no), the inverse associations were essentially unchanged
(data not shown). When dietary folate intake alone was used in
the analysis, the results remained (data not shown). In addition,
we stratified data by folic acid–containing supplement use status;
our findings were generally consistent in both users and nonusers
(Table 3).
As shown in Table 4, serum folate was inversely associated
with incidence of hypertension in the subgroup with serum fo-
late data available. The incidence of hypertension was reduced
by 51% in participants in the highest quintile compared with
those in the lowest quintile of serum folate concentrations (HR:
0.49; 95% CI: 0.33, 0.71; P-trend , 0.01). When further ad-
justed for dietary intakes of total energy, sodium, potassium,
calcium, a-linolenic acid, linolenic acid, and long-chain omega-
3 fatty acids, the inverse association was essentially unchanged:
whites (HR: 0.44; 95% CI: 0.25, 0.77; P-trend , 0.01) and
African Americans (HR: 0.48; 95% CI: 0.23, 1.00; P-trend ,
0.01; P-interaction = 0.27).
Several sensitivity analyses were conducted to test the ro-
bustness of our main findings. First, to balance the observed
covariates, we used a propensity score method to compare the 2
extreme quintile groups as an example. The HR in the highest
quintile of folate intake compared with the lowest quintile was
0.54 (95% CI: 0.40, 0.73; P-trend , 0.01) with adjustment for
propensity scores (quintiles), which were derived from the same
covariates in the main analysis; the corresponding HR was 0.58
(95% CI: 0.40, 0.85; P-trend , 0.01) when adjusted for pro-
pensity scores (quintiles) derived from the covariates in the final
model with additional dietary variables (ie, magnesium, caf-
feine, protein, and fiber). Second, when we further adjusted
baseline systolic blood pressure and glucose concentration in the
model, the inverse association between folate intake and hy-
pertension were essentially unchanged. Third, when we chose
not to update dietary information for incident cases defined only
on the basis of antihypertensive medication use at examination
years 7 and 20, because these participants were more likely to
change their dietary habits after receiving a diagnosis of hy-
pertension, the results were not appreciably altered. Fourth,
when we used the most-recent dietary information in the anal-
ysis, the results again did not change appreciable. Fifth, when
we recalculated the person-time for the 412 cases that were
diagnosed before a follow-up visit using the middle point be-
tween the current and last visits, the results were essentially
unchanged. Finally, because vitamin B-6 and B-12 intakes were
assessed only at examination years 7 and 20, we reexamined
folate intake in relation to incidence of hypertension using ex-
amination year 7 as baseline. After adjustment for the same
covariates in model 2 (Table 2), the HR (the highest compared
with lowest quintile) was 0.48 (95% CI: 0.36, 0.65; P-trend ,
0.01). After further adjustment for intakes of vitamin B-6 and B-12,
the inverse association remained.
To explore potential mechanisms, we examined the relation
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found that serum folate concentrations were significantly inversely
related to serum homocysteine concentrations. Spearman’s partial
correlation coefficient was20.46 (P, 0.01) between serum folate
and homocysteine with adjustment for age, sex, race, and study
center. Also, serum homocysteine concentrations were positively
associated with BP. Systolic and diastolic BP were higher by 0.63
mm Hg (95% CI: 0.13, 1.13; P = 0.01) and 0.55 mm Hg (95% CI:
0.14, 0.96; P , 0.01), respectively, with a 5-lmol/L increment in
serum homocysteine (;1 SD) with adjustment for potential con-
founders. In addition, higher homocysteine concentrations were
also associated with elevated incidence of hypertension (data not
shown).
DISCUSSION
In this 20-y follow-up prospective study, we found an inverse
association between folate intake and incidence of hypertension,
and this inverse association was stronger in whites than in African
Americans. This inverse association was fairly robust and further
supported by serum folate data from a subset of participants. Our
findings are less likely to be explained by residual confounding or
confounding by unmeasured factors, because the results persisted
with adjustment for many potential confounders and in various
sensitivity analyses.
Our findings agree with those from previous studies. An inverse
relation between folate intake and incidence of hypertension was
found in the Nurses’ Health Study, although it was exclusively
conducted in women (8). In addition, some clinical studies have
shown that high-dose supplemental folic acid may be associated
with reduced BP (7, 24, 25). For example, a small scale study
documented an average drop in systolic and diastolic BP of 4.5 and
5.3 mm Hg, respectively, in postmenopausal women who received
a daily dose of 15mg of 5-methyltetrahydrofolate for 3 wk (7). Yet,
there is also some contradictory evidence. A meta-analysis of 8
randomized trials concluded that dietary supplementation with
folic acid had no significant effects on cardiovascular events within
5 y (26). However, the outcome in this meta-analysis referred to
major coronary events and stroke and not specifically to hyper-
tension. Also, short-term follow-up clinical trials only focusing on
supplement use cannot rule out a long-term effect (ie, 20 y) of folate
intake from both foods and supplements, as found in this study.
It was hypothesized that the potential antihypertensive effect
of folate intake may be mainly due to a reduction in blood
homocysteine concentrations through remethylation of homo-
cysteine back to methionine (27). However, the findings from our
study seemed not to support this hypothesis. When we further
controlled for serum homocysteine in model 3 (Table 4), the
association (quartile 5 compared with quartile 1) was slightly
attenuated. Previous studies also suggested other mechanisms,
such as an interaction with endothelial nitric oxide synthase and
endothelium-derived hyperpolarizing factor, which may improve
endothelial function independent of its homocysteine-lowering
effect (28). Nonetheless, we do not have data from the current
study to test these hypotheses. Further studies are needed to
elucidate the mechanisms.
In this study, we found that race significantly modified the in-
verse association between folate intake and hypertension, with
a greater benefit in whites. Race was also indicated to modify the
folate-CVD relation in a previous study (20). In our study, this
modification effect may be explained, at least partially, by the
higher intake of folate in whites [median (25th–75th percentiles):
200.9 (144.9–282.2) lg  1000 kcal21  d21] than in African
Americans ([142.7 (106.9–204.5) lg  1000 kcal21  d21] given
the dose-response relation between folate intake and hypertension.
One concern is the accuracy of dietary assessment (29). The
food-frequency questionnaire used in the current study, however,
has been validated and shown to reasonably reflect long-term
dietary intake (30). Also, intakes of many nutrients have suc-
cessfully predicted CVD risk factors, including hypertension in
previous CARDIA studies (17, 18, 31–33). In addition, possible
measurement error in dietary assessment was somewhat reduced
by using repeated measurements and cumulative average diet
intakes. Moreover, the Spearman correlation coefficients of folate
intake with serum folate concentrations at different visits ranged
TABLE 4
Multivariable-adjusted HRs (95% CIs) of incident hypertension by quintile of serum folate in a subset of the cohort (n = 1445)1
Quintile of serum folate
P-trend21 (lowest) 2 3 4 5 (highest)
Serum folate (nmol/L)3 4.20 (3.20–4.83) 6.53 (5.95–6.97) 8.67 (8.03–9.20) 11.17 (10.40–12.10) 15.97 (14.33–18.80)
No. of events/participants 129/290 79/288 52/287 58/291 45/289
Model 14 1.00 0.52 (0.39, 0.69) 0.37 (0.27, 0.52) 0.44 (0.32–0.60) 0.39 (0.27–0.56) ,0.01
Model 25 1.00 0.54 (0.40, 0.71) 0.40 (0.29, 0.56) 0.47 (0.34, 0.65) 0.47 (0.32, 0.68) ,0.01
Model 36 1.00 0.56 (0.42, 0.75) 0.42 (0.30, 0.59) 0.51 (0.37, 0.71) 0.49 (0.33, 0.71) ,0.01
Model 47 1.00 0.56 (0.42, 0.75) 0.43 (0.31, 0.61) 0.52 (0.37, 0.73) 0.55 (0.37, 0.82) ,0.01
1 All models were constructed by using Cox proportional hazards regression analysis. Because serum biomarker was used as exposure, we considered
model 3 as the final model.
2 Ordinal variables using medians in each quintile were created for the trend tests.
3 Values are medians; IQRs in parentheses.
4 Adjusted for age, sex, race (African American or white), and study center.
5 Additionally adjusted for BMI (continuous), physical activity (quintile), education (,12, 12–15.9, or 16 y), smoking status (nonsmokers, former
smokers, or current smokers with pack-years between 1 and 4, between 5 and 10, or 11 y), alcohol consumption (0, 0.1–14.9, 15.0–29.9, or 30 mL/d), and
family history of hypertension (yes or no).
6 Additionally adjusted for serum concentrations (quintiles) of vitamin B-6 and vitamin B-12.
7 Additionally adjusted for dietary intakes (quintiles) of total energy, sodium, potassium, calcium, a-linolenic acid, linoleic acid, and long-chain omega-3
fatty acids.
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from 0.37 to 0.59, which are reasonably high and further support
the validity of our dietary assessment.
Another concern is that the observed inverse associations may
reflect consumption of other potentially beneficial components of
foods rich in folate, such as green leafy vegetables, or plant food
patterns, including fruit, vegetables, nuts, legumes, and whole-
and refined-grain products (34). However, the serum folate data
confirmed the potential beneficial effect of folate on BP.
Other limitations also need to be considered. First, data on
vitamins B-6 and B-12 intakes were unavailable in 1985, which
limited our ability to consider the intakes of these 2 vitamins as
potential confounders in the main analysis. However, when we
used exam year 7 as the baseline, similar inverse associations
between cumulative average folate intake and incidence of hy-
pertension were documented after adjustment for these 2 vita-
mins in a subset of the cohort. Second, the generalizability of our
findings may be limited because CARDIA was not a nationally
representative sample.
A couple of other strengths enhanced the validity of this study.
First, this study had a prospective design, a relatively large bi-
racial sample, a 20-y follow-up, and especially that the partici-
pants at baseline were aged 18–30 y, which together enabled us to
study the evolution of CVD risk by following the course of BP
and the appearance of incident hypertension from young adult-
hood. Second, the BP of our participants was directly measured by
trained personnel using standardized procedures, rather than being
self-reported, which substantially reduced measurement error.
In conclusion, our findings provide prospective evidence that
a higher intake of folate is associated with a lower incidence of
hypertension. This inverse association was more pronounced in
whites than in African Americans. Further studies are warranted
to establish causal inference.
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